The finding that PTPN11 is a well-established strong potential therapeutic target in LUAD and AMPD2 is a novel potential therapeutic target in HNSCC, despite showing no significant differences at the transcriptomic or proteomic levels (FDR > 0.05), emphasizes the importance of proteogenomic data [34]. Here, AMPD2 is linked to head and neck squamous cell carcinoma.